Good Morning AGXPE Membership,
The AGXPE is excited to see that the FDAs G-SRS system, a freely distributable substance registration system that is compliant with the ISO IDMP Substance Standard 11238, Go-Live version update is here! As we have welcomed Larry Callahan to the AGXPE Conferences in 2015 & 2016 to use our platform to communicate this outstanding opportunity to our membership & industry, we would like to help the FDA GInAS team communicate an opportunity to attend their upcoming meeting. The meeting is approaching quickly, so please see details below:
The 2017 GInAS meeting will be held at USP headquarters at 12601 Twinbrook Parkway on Wednesday October 11, 2017. The meeting will coincide with the release of the Global Substance Registration System (G-SRS) version 2.0. The G-SRS is a freely distributable substance registration that is compliant with the ISO IDMP Substance Standard 11238. The system can be used by both industry and regulators throughout the world and contain a bolus of public domain data on substances in medicinal products or clinical development. The meeting will discuss the new system, the ISO IDMP standards and implementation guides and will have presentations by a number of collaborators and partners in this effort.
In addition to the one day meeting a session for developers and implementers will be held at held at NCATs Shady Grove Location. There is no charge to attend either meeting and we look forward to your attendance and participation to further development of the G-SRS. Please reach out to any of the GInAS team members listed below if you have any questions and feel free to share this invitation with anyone who may have an interest.
The agenda and registration can be found at https://tripod.nih.gov/ginas/#/meetings/ginas2017. The agenda is at the bottom of the page.
Information about travelling to USP can be found at
Larry Callahan email@example.com
Tyler Peryea firstname.lastname@example.org
Noel Southall email@example.com
Frank Switzer firstname.lastname@example.org
Geetha Mandava email@example.com